Two cases of treatment with aromatase inhibitors and development of miliary osteoma cutis—Is there an association?

Schadler, Eric D.; Mehlis, Stephanie; Cibull, Thomas; Ortel, Bernhard

doi:10.1016/j.jdcr.2018.05.007

Cited by 4 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Onset of dermatology-related adverse events ranged from 2 days to 9 months. Commonly reported side effects included unspecified rash, pruritus, various immune-mediated reactions, vulvovaginal atrophy, and alopecia ( Balagula et al, 2011 ; Budel et al, 1986 ; Crockett and Burkemper, 2011 ; De Placido et al, 2018 ; Jhaveri et al, 2007 ; Moscetti et al, 2015 ; Ooi and Jaffar, 2019 ; Paridaens et al, 2003 ; Pellegrini et al, 2009 ; Pokhai et al, 2014 ; Potter and Moore, 2013 ; Rossi et al, 2013 ; Schadler et al, 2018 ; Sestak et al, 2014 ; Shoda et al, 2005 ; Sonke et al, 2018 ; Stein et al, 1990 ; Stratakis and Chrousos, 1994 ; Tominaga et al, 2003 ; Trancart et al, 2008 ; Tryfonidis et al, 2016 ; Williams and Leslie, 1987 ; Wong et al, 2008 ; Yang et al, 2020 ; Zarkavelis et al, 2016 ).…”

Section: Dermatologic Adverse Eventsmentioning

confidence: 99%

Art of prevention: The importance of dermatologic care when using aromatase inhibitors

Behbahani

Geisler

Kolla

et al. 2021

International Journal of Women's Dermatology

View full text Add to dashboard Cite

As of January 2021, there are more than 3.8 million women in the United States with a history of breast cancer. The current standard of care for breast cancer involves surgical resection, radiation therapy, adjuvant endocrine therapy, and/or adjuvant chemotherapy. Aromatase inhibitors (AIs) are the gold standard for endocrine therapy in postmenopausal women. Dermatologic adverse events (dAEs) associated with AIs are rare but have been reported in the literature. Commonly reported dAEs include unspecified rash, pruritus, alopecia, vulvovaginal atrophy, vasculitis, and autoimmune/connective tissue disorders. Appropriate preventative strategies and careful management considerations have the potential to optimize the comprehensive care of patients with cancer and improve quality of life. Furthermore, prevention of dAEs can lead to a reduction in cancer treatment interruptions and discontinuations. Herein, we characterize dAEs of AIs and discuss preventative management to reduce the incidence of AI therapy interruption.

show abstract